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Abstract
The pneumococcal antigens contained in the polysaccharide (PPV23) and conjugate (7-valent, PCV7; 13-valent, PCV13) vaccines have
been chosen since they represent the serotypes that more frequently cause invasive pneumococcal disease. Whether these vaccines
cover the serotypes most frequently isolated in haematology patients is unclear. The serotype distribution among Streptococcus pneumo-
niae in 25 consecutive pneumococcal infections that occurred over the last 3 years in two French haematology departments was investi-
gated. The pneumococcal vaccines PCV7, PCV13 and PPV23 were found to cover 76, 84 and 92%, respectively, of the serotypes found.
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Patients with haematological malignancies, especially those
treated with haematopoietic stem cell transplant (HSCT), are
at high risk of Streptococcus pneumoniae infections [1,2], due
to impaired spleen function related to total body irradiation,
chronic graft-versus-host disease (GVHD) and decreased pro-
duction and function of anti-S. pneumoniae antibodies [3,4].
Two anti-pneumococcal vaccines are currently available:
the 23-valent polysaccharide vaccine Pneumovax (PPV23), and
the heptavalent conjugate vaccine Prevnar (PCV7). All seven
PCV7 antigens (serotype 4-, 6B-, 9V-, 14-, 18C-, 19F- and 23F-
speciﬁc) are included in those of PPV23, which contains 16
additional antigens. Covalent conjugation of a polysaccharide
to a protein carrier converts the immune response from T-cell
independent to T-cell dependent, resulting in a stronger and
longer-lasting response. This could explain the poor immuno-
genicity of PPV23 [4–6] when compared with PCV7 [7,8].
However, PPV23 offers a broader spectrum of serotype cov-
erage. Therefore, PCV7 and PPV23 could be considered as
complementary. Furthermore, PCV7, but not PPV23, reduces
pneumococcal carriage [9]. Among the several future conju-
gate vaccines, including a PCV10 adding three valences (for
serotypes 1, 5 and 7F), and PCV13 adding six valences (for
serotypes 1, 3, 5, 6A, 7F and 19A) to those of PCV7, PCV13
is currently studied in the healthy population [10].
Whether these vaccines cover the main serotypes infect-
ing immunocompromised hosts is not well known. The aim
of this study was to investigate the serotype distribution of
S. pneumoniae in invasive pneumococcal infections observed
in haematology patients in the Ile de France region, and the
proportion of patients covered by the anti-pneumococcal
vaccines over a recent 3-year period.
Methods
This was a retrospective study performed in two haematology
departments in Paris over a 3-year period. All pneumococci
isolated between January 2004 and December 2006 in a
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haematology department each at Henri Mondor and Saint-Louis
teaching hospitals were identiﬁed from the laboratory
registries. Only patients with invasive infections were selected.
Invasive pneumococcal infection was deﬁned as presence of
S. pneumoniae in blood or cerebrospinal ﬂuid, irrespective of
clinical symptoms, or in a bronchoscopy specimen from
patients with clinical and/or radiological evidence of pneumonia.
Serotyping was performed at the CNRP in Paris according to a
previously published method [11]. MIC of antibiotics were
determined.
Results
Among the 40 consecutive episodes of invasive pneumococ-
cal infection considered, serotyping was performed for 25
episodes involving 22 patients. The 15 strains from the
remaining episodes were either not available or did not
regrow, so that the serotype could not be determined. The
median age of the 22 patients was 54 years (26–73) and the
sex ratio (M/F) was 13/9. There were nine allogeneic—all
with GVHD—and eight autologous HSCT recipients. The
allogeneic HSCT recipients had been transplanted for acute
myeloid leukaemia (n = 4) and, one each, for acute lympho-
blastic leukaemia (ALL), chronic myeloid leukaemia, myelo-
dysplastic syndrome, Hodgkin disease and myeloma following
a reduced intensity regimen in ﬁve of them. The autologous
HSCT recipients had been transplanted for lymphoma
(n = 4) or myeloma (n = 4). In case of multiple transplants,
the allogeneic HSCT was always the last transplant per-
formed, and the patients who received an autologous HSCT
before an allogeneic HSCT (n = 3) were counted in the allo-
geneic HSCT group. The non-transplanted patients included
four patients with chronic lymphocytic leukaemia, and one
patient with ALL. None was splenectomized. Nine patients
received steroids, and 13 received oral penicillin.
Most episodes (21/25) were due to bronchopneumonia or
pneumonia, whereas four were due to sepsis with positive
blood cultures only. No case of meningitis or otitis was
observed. Four allogeneic HSCT recipients had been previ-
ously vaccinated, either with PCV7 or PPV23, or both. The
pneumococci were susceptible to penicillin in six (24%), of
intermediate susceptibility in 13 (52%), and resistant in six
(24%) cases, respectively. Three patients died from invasive
pneumococcal infection, all relapses of a previous episode due
to pneumococci of the same serotype (19F, 35B and 9V).
The frequency of the different serotypes is presented in
Table 1. Among the 25 serotyped strains, the serotype cov-
erage by the vaccine was 19 (76%), 21 (84%) and 23 (92%)
for PCV7, PCV13 and PPV23, respectively.
Discussion
Pneumococcal infections are signiﬁcant causes of morbidity
and mortality after allogeneic HSCT, both early and late after
transplantation [2]. In the prospective study by the European
Group for Blood and Marrow Transplant (EBMT), four of
the ten deaths observed occurred before 6 months, leading
us to reconsider the usual ‘late infection’ label of pneumo-
coccal infection in HSCT patients [2]. The mortality rate is
also high in non-transplanted patients, reported to be 16%
within 2 weeks of diagnosis [12]. Penicillin prophylaxis does
not universally prevent pneumococcal infection, due to the
increasing rate of penicillin resistance [2]. Therefore, pneu-
mococcal vaccination is recommended for HSCT recipients
both by the EBMT [13] and the CDC [14]. Recommenda-
tions are lacking for most of the other patients with haema-
tological malignancies.
There are two requirements if one is to predict the possi-
ble clinical protection offered by a vaccination programme:
(i) knowledge of the immune response induced by the vac-
cine(s); and (ii) for bacteria with multiple serotypes such as
S. pneumoniae, knowledge of the epidemiology of the more
frequent infecting strains in the targeted population. Indeed,
considering the rarity of the event after HSCT (5–18 invasive
infections/1000 transplant patients) [2,15], it is impossible to
demonstrate a signiﬁcant reduction, due to immunization, in
the number of cases, considering the number of patients
who can realistically be recruited.
Two prospective studies in allogeneic HSCT recipients,
one in adults [16] and one in children [17], using different
timings of immunization, have shown that the rates of
response to all seven PCV7 antigens are between 65 and
75% after three doses of PCV7. Kumar et al. [8] have shown
TABLE 1. Distribution of pneumococcal serotypes and their
coverage by the different pneumococcal vaccines
Serotype
No. of
episodes
Covered by the indicated
pneumococcal vaccine
PCV7 PCV13 PPV23
3 1 + +
6B 1 + + +
9V 7 + + +
11A 1 +
14 2 + + +
15B 1 +
18C 1 + + +
19A 1 + +
19F 6 + + +
23A 1
23F 2 + + +
35B 1
Total 25 19 (76%) 21 (84%) 23 (92%)
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that PCV7 is more immunogenic than PPV23 after allogeneic
HSCT. A recent study from the EBMT Infectious Diseases
Working Party showed that starting vaccination with three
doses of PCV7 3 months after HSCT was not inferior to
starting at 9 months [18]. Patel et al. [19] reported their
experience with PCV7 given to 13 transplanted children
between 15 and 24 months after transplantation in a prede-
ﬁned immunization schedule with results consistent with
those of the three above-mentioned studies. Data also exist
for autologous transplant [20] or splenectomized patients
with haematological malignancies [21]. Of interest, four of
the ﬁve non-HSCT patients of this study had chronic lym-
phocytic leukaemia. In this population, the immune response
to the polysaccharide is poor—around 10%—even after mul-
tiple doses of granulocyte-macrophage colony-stimulating fac-
tor [22], and the response to PCV7 is unknown so far.
Consequently, this population does not beneﬁt from any rec-
ommendation, except for immune globulins in case of severe
hypogammaglobulinaemia.
On the other hand, few data exist concerning the pneu-
mococcal serotypes isolated from haematology patients.
Since pneumococcal epidemiology varies throughout the
world, but also depending upon age, antibiotic use, or vacci-
nation programmes [9], it is important to have speciﬁc data
for immunocompromised hosts in given areas, and an
informed guess about the potential beneﬁt of the available
vaccines. A retrospective study carried out in the USA
showed that among 17 children who had received a stem
cell transplant and who were infected by pneumococci dur-
ing the period 1993–1998, all serotypes were within the
spectrum of PCV7 [23]. However, due to the shift in pneu-
mococcal serotypes after the introduction of the conjugate
vaccine [26,27], the actual pertinence of these data may be
questioned.
A recent study carried out in Canada has shown that
among 13 pneumococcal strains isolated from HSCT recipi-
ents, 10 were within the spectrum of PCV7, and all were
covered by PPV23 [24].
Our study shows that in the Paris area (Ile de France
region), only 8% of the 25 invasive pneumococcal strains
were not covered by either of the currently available vac-
cines. Most of the strains were covered by PPV23 (92%), and
PCV7 (76%), and also by the new conjugate vaccine PCV13
(84%). By comparison, among invasive strains serotyped at
the CNRP and originating from the same geographical area,
the percentage of serotypes covered was 40, 73 and 85%, by
PCV7, PCV13 and PPV23, respectively. It should be noted
that among the three patients who died from pneumococcal
infection, infection was due to the same serotype that caused
a previous episode, and two of these three strains were of a
serotype covered by both PCV7 and PPV23 (i.e. 19F and
9V). Vaccination given after the ﬁrst infection could have
avoided the occurrence of the second episode, and death in
two of them.
It has been suggested that wide use of PCV7 in the com-
munity could induce switches in the predominant serotypes
to those outside the spectrum of the vaccines, concomitantly
with increasing rates of antibiotic-resistant strains [25–27].
However, due to the low number of HSCT patients in the
community, we do not think this should limit the use of
pneumococcal vaccine in this population.
These data strongly support the development of vaccina-
tion programmes with both PCV7 and PPV23 in high-risk
haematology patients, and prospective studies with PCV13 in
the Ile de France region.
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